Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Eye & ENT Hospital of Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT05011227
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT05005468
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 39
- Registration Number
- NCT05003700
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Di Wu
- Target Recruit Count
- 66
- Registration Number
- NCT04979585
- Locations
- 🇨🇳
The first hospital of Jilin University, Changchun, Jilin, China
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 172
- Registration Number
- NCT04974944
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT04974827
- Locations
- 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China
Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT04947956
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04948125
- Locations
- 🇨🇳
Henan cancer hospital/The affiliated Cancer Hospital of ZhengZhou university, Henan, China
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 188
- Registration Number
- NCT04944914
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 78
- Registration Number
- NCT04930315
- Locations
- 🇨🇳
the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.